Key result
Multivessel percutaneous coronary intervention significantly reduced the 1-year rate of major adverse cardiac events to 7.3% compared to 13.8% with culprit-only intervention in STEMI patients with multivessel disease.
Why the study?
Does multivessel percutaneous coronary intervention reduce major adverse cardiac events in STEMI patients with multivessel disease without cardiogenic shock compared to culprit-only intervention?
Cohort (n=1,406)
Yes
Does multivessel percutaneous coronary intervention reduce major adverse cardiac events in STEMI patients with multivessel disease without cardiogenic shock compared to culprit-only intervention?
In STEMI patients with multivessel disease without cardiogenic shock, multivessel PCI during admission significantly reduces the rate of major adverse cardiac events at one year compared to culprit-only PCI.
Answers are grounded in this paper and cite their sources.
May support culprit-only PCI in stable STEMI with multivessel disease; leaves open benefit of complete revascularization pending randomized confirmation.
BACKGROUND: The clinical significance of complete revascularization for ST segment elevation myocardial infarction (STEMI) patients during admission is still debatable. METHODS: A total of 1406 STEMI patients from the Korean Myocardial Infarction Registry with multivessel diseases without cardiogenic shock who underwent primary percutaneous coronary intervention (PPCI) were analyzed. We used propensity score matching (PSM) to control differences of baseline characteristics between culprit only intervention (CP) and multivessel percutaneous coronary interventions (MP), and between double vessel disease (DVD) and triple vessel disease (TVD). The major adverse cardiac event (MACE) was analyzed for one year after discharge. RESULTS: TVD patients showed higher incidence of MACE (14.2% vs. 8.6%, P = 0.01), any cause of revascularization (10.6% vs. 5.9%, P = 0.01), and repeated PCI (9.5% vs. 5.7%, P = 0.02), as compared to DVD patients during one year after discharge. MP reduced MACE effectively (7.3% vs. 13.8%, P = 0.03), as compared to CP for one year, but all cause of death (1.6% vs. 3.2%, P = 0.38), MI (0.4% vs. 0.8%, P = 1.00), and any cause of revascularization (5.3% vs. 9.7%, P = 0.09) were comparable in the two treatment groups. CONCLUSIONS: STEMI patients with TVD showed higher rate of MACE, as compared to DVD. MP performed during PPCI or ad hoc during admission for STEMI patients without cardiogenic shock showed lower rate of MACE in this large scaled database. Therefore, MP could be considered as an effective treatment option for STEMI patients without cardiogenic shock.
No takes yet. Share an insight, caveat, or question.
Ryu et al. (2015) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) with multivessel coronary disease (n=1,406). Multivessel percutaneous coronary intervention vs. Culprit vessel only percutaneous coronary intervention was evaluated on Major adverse cardiac events (MACE) at 1 year (p=0.03). Multivessel percutaneous coronary intervention significantly reduced the 1-year rate of major adverse cardiac events to 7.3% compared to 13.8% with culprit-only intervention in STEMI patients with multivessel disease.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: